- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MGC Pharma Sees Growth in Prescriptions for November
MGC Pharmaceuticals announced it has seen 40 percent growth since the end of October 2019 in the number of prescribed cannabinoid medicines.
MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 26) it has seen 40 percent growth since the end of October 2019 in the number of prescribed cannabinoid medicines in Australia, the United Kingdom and Brazil.
As quoted in the press release:
Key Highlights:
Prescriptions have increased 40% from 1,000 at the end of October 2019 to pass 1,400 as at 25 November 2019
Unique patient numbers have increased 28% in the period since 31 October 2019
An increasing number of return patients for MGC Pharma products is being seen, contributing to the prescription growth rate
Further demonstrating the near-term revenue generating potential of the Company based on its phytocannabinoid derived medicines to patients in Australia, the U.K and now with access to Brazil and key Latin American markets
Average Prescription orders are currently at 22 per business day
Click here to read the full press release.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â